Correction: Safety of immune checkpoint inhibitor rechallenge after discontinuation for grade ≥2 immune-related adverse events in patients with cancer


This paper has been updated since first published to revise affiliation 10 to ‘+Univ. Bordeaux, INSERM, BPH, U1219, F-33000 Bordeaux, France’.